Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction

European Heart Journal

Volumn 20, Issue 11, 1999, Pages 819-826

  Maas, A C P ^a   Van Domburg, R T ^a   Deckers, J W ^a   Vermeer, F ^b   Remme, W J ^c   Kamp, O ^d   Cats, V Manger ^e   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zuiderziekenhuis   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Follow up studies; Myocardial infarction; Risk factors; Survival; Thrombolysis

Indexed keywords

STREPTOKINASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART REINFARCTION; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NETHERLANDS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY;

EID: 0033152339     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1443     Document Type: Article

References (28)

1. Gruppo italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397-401.
2. Simoons ML, Serruys PW, van Den Brand M et al. Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985; ii: 578-82.
3. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465-71.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988; ii: 350-60.
5. Wilcox RG, Von Der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-scandinavian study of early thrombolysis (ASSET). Lancet 1988; ii: 525-30.
6. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988; i: 545-9.
7. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-66.
8. EMERAS (Estudio Multicentrico Estreptoquinasal Repulicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-72.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
10. Simoons ML, Vos J, Tijssen JGP et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the interuniversity cardiology institute of the netherlands. J Am Coll Cardiol 1989; 14: 1609-15
11. Lenderink T, Simoons ML, Van Es GA, Van de Werf F, Verstraete M, Arnold AER for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995; 92: 1110-6.
12. Hills WS, Chaimberlain DA, de Bono DP, Fox KAA, Murray RG, Julian DG for the AIMS study group. Intravenous anistreplase in acute myocardial infarction: Continued reduction in mortality up to 5 years: Long-term results of the AIMS study (abstr). Eur Heart J 1992; 13 (Suppl): 305.
13. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol 1992; 20: 1452-9.
14. Terrin ML, Williams DO, Kleiman NS et al. Two- And three-years results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993; 22: 1763-72.
15. Vermeer F, Simoons ML, de Zwaan C et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow-up report of the randomised multi-centre trial conducted by the Interuniversity Cardiology Institute of the Netherlands. Br Heart J 1988; 59: 527-34.
16. Simoons ML, Serruys PW, van Den Brand M et al. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717-28.
17. Serruys PW, Simoons ML, Suryapranata H et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986; 7: 729-42.
18. Boersma H, van Der Vlugt MJ, Arnold AE, Deckers JW, Simoons ML. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Eur Heart J 1996; 17: 64-75.
19. Launbjerg J, Fruergaard P, Madsen JK, Mortensen LS, Hansen JF. Ten year mortality in patients with suspected acute myocardial infarction. Br Med J 1994; 308: 1196-9.
20. Guazzi MD, Bussotti M, Grancini L et al. Evidence of multifocal activity of coronary disease in patients with acute myocardial infarction. Circulation 1997; 96: 1145-51.
21. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
22. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
23. Madsen JK, Grande P, Saunamaki K et al. on behalf of the DANAMI Study Group. Danish multicenter randomised study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997; 96: 748-55.
24. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Eng J Med 1996; 335: 1001-9.
25. Jukema JW, Bruschke AV, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
26. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
27. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
28. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New Engl J Med 1992; 327: 669-77.